In vitro synergism of combinations of colistin with selected antibiotics against colistin-resistant Acinetobacter baumannii

Perçin, Duygu; Akyol, Selcan; Ünüvar, Gamze Kalın

doi:10.3205/dgkh000234

Cited by 17 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the clinical data of colistin plus rifampicin treatment compared to colistin monotherapy did not show a significant difference in clinical response 19 . The synergy rate of the COL/SUL combination in this present study was greater than that of a previous study (50% synergy rate) which showed colistin plus vancomycin was most effective (90% synergy rate) 18 . This is the first report of in vitro synergistic activity of COL/FOS and SUL/FOS combinations against CoR-AB clinical isolates.…”

Section: Discussioncontrasting

confidence: 84%

“…Several antibiotic combinations have been proposed as therapeutic choices to treat CoR-AB. Such as colistin plus rifampicin or vancomycin were found more synergistic and effective against CoR-AB clinical isolates than other combinations 17 , 18 . However, the colistin plus rifampicin combination did not show a significant clinical response when compared with colistin monotherapy 19 .…”

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

Overcoming addition of phosphoethanolamine to lipid A mediated colistin resistance in Acinetobacter baumannii clinical isolates with colistin–sulbactam combination therapy

Srisakul

Wannigama

Higgins

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Overcoming colistin-resistant Acinetobacter baumannii (CoR-AB) has become a major concern due to the lack of effective antibiotics. This study aimed to explore the prevalence of CoR-AB clinical isolates in Thailand, their mechanisms of resistance, and test the efficacy of colistin plus sulbactam against CoR-AB isolates. The colistin resistance rate among carbapenem-resistant A. baumannii was 15.14%. The mcr gene or its variants were not detected in CoR-AB isolates by PCR screening. The lipid A mass spectra of CoR-AB isolates showed the additional [M–H]− ion peak at m/z = 2034 that correlated to the phosphoethanolamine (pEtN) addition to lipid A (N = 27/30). The important amino acid substitutions were found at position S14P, A138T, A227V in PmrB that are associated with overexpression of the pEtN transferase (PmrC) and contributed the pEtN addition. The lipopolysacccharide production genes (lpxACD) were not related to lipid A mass spectra. A colistin plus sulbactam combination exhibited the synergy rate at 86.7% against CoR-AB isolates compare to sulbactam (85.89% resistance) or colistin (15.14% resistance) alone. The excellent synergistic activity of colistin plus sulbactam combination has the potential for the treatment of CoR-AB infections.

show abstract

Section: Discussioncontrasting

confidence: 84%

Section: Introductionmentioning

confidence: 95%

Overcoming addition of phosphoethanolamine to lipid A mediated colistin resistance in Acinetobacter baumannii clinical isolates with colistin–sulbactam combination therapy

Srisakul

Wannigama

Higgins

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…At each time point (i.e., 2, 4, 6, 12, and 24 h), 200 μl of the bacterial suspension was serially diluted 10-fold and then transferred into LB agar plates to enumerate the number of bacteria. These plates were incubated statically at 37°C for 18 h. The synergy effect was defined as a >2 log 10 decrease in CFU/ml after 24 h of the combination treatment relative to that after treatment with colistin or chrysin individually (Percin et al, 2014 ).…”

Section: Methodsmentioning

confidence: 99%

In vitro and in vivo synergistic effect of chrysin in combination with colistin against Acinetobacter baumannii

Zhao

Liu²,

Feng³

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

Acinetobacter baumannii is an opportunistic pathogen that is primarily associated with nosocomial infections. With the rise in cases of acquired drug resistance, A. baumannii is gaining resistance to conventional antimicrobial drugs and even to the last line of antibiotics, such as colistin. Hence, the application of the synergistic combination of an antibiotic and a non-antibacterial agent is being contemplated as a new alternative therapeutic approach. Chrysin is a component of honey with anti-inflammatory and antioxidant properties. In this study, we evaluated the antibacterial activity of chrysin in combination with colistin against A. baumannii both in vitro and in vivo, as well as the cytotoxicity of chrysin with or without colistin. Our results revealed that chrysin and colistin exerted synergistic effects against A. baumannii by damaging the extracellular membrane and modifying the bacterial membrane potential. The chrysin/colistin combination group demonstrated an inhibitory effect on biofilm formation. In conclusion, it is expected that the synergy between these drugs can allow the use of a lower concentration of colistin for the treatment of A. baumannii infections, thereby reducing dose-dependent side effects. Thus, a combination therapy of chrysin/colistin may provide a new therapeutic option for controlling A. baumannii infections.

show abstract

“…The colistin-based combinations will serve to: (i) overcome the resistance against colistin and other antimicrobial agents; (ii) increase the combination efficacy over monotherapy; and (iii) decrease colistinassociated toxicities. Previous studies have shown the existence of synergistic interactions when colistin is combined with antimicrobials against various Gram-negative clinical isolates [11][12][13]. However, to the best of our knowledge, there is no such study for colistin-based combination against Gram-negative clinical isolates from Saudi Arabia.…”

Section: Introductionmentioning

confidence: 98%

Synergistic activities of colistin combined with other antimicrobial agents against colistin-resistant Acinetobacter baumannii clinical isolates

Almutairi

2022

PLoS ONE

View full text Add to dashboard Cite

Emerging resistance to colistin in Acinetobacter baumannii clinical strains is concerning because of the limited therapeutic choices for these important clinical pathogens. We studied the in vitro activities of different colistin-based antimicrobial agent combinations against colistin-resistant Acinetobacter baumannii. Fourteen clinical isolates of colistin-resistant Acinetobacter baumannii were obtained between 2015 and 2016. To identify colistin-based combinations with synergistic activities, multiple two antimicrobial combinations based on 8 commercially available drugs were evaluated by the checkerboard method. The most effective colistin-based combinations were vancomycin, aztreonam, ceftazidime and imipenem which showed synergistic activities against all examined strains. Colistin-rifampin showed synergy against four strains. Colistin-tigecycline and colistin-amikacin mostly showed indifferent results. By using the checkerboard tests, we were able to find the most promising colistin-based combinations that may provide more therapeutic options against colistin-resistant Acinetobacter baumannii.

show abstract

In vitro synergism of combinations of colistin with selected antibiotics against colistin-resistant Acinetobacter baumannii

Cited by 17 publications

References 17 publications

Overcoming addition of phosphoethanolamine to lipid A mediated colistin resistance in Acinetobacter baumannii clinical isolates with colistin–sulbactam combination therapy

Overcoming addition of phosphoethanolamine to lipid A mediated colistin resistance in Acinetobacter baumannii clinical isolates with colistin–sulbactam combination therapy

In vitro and in vivo synergistic effect of chrysin in combination with colistin against Acinetobacter baumannii

Synergistic activities of colistin combined with other antimicrobial agents against colistin-resistant Acinetobacter baumannii clinical isolates

Contact Info

Product

Resources

About